Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 24

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 24
---
 2025, such shares would represent approximately 98.9% of total number of Ordinary
Shares issued and outstanding.

Furthermore, the market price of our Depositary Sharescould decline as a result of actual or anticipated future issuances, including the issuance of shares from Series L Warrant
exercises, which will result in substantial dilution to existing shareholders. The existence of the potential additional Depositary Shares
in the public market or the perception of potential dilution from future issuances could depress the market price of our Depositary Shares
and could impair our ability to raise capital through the sale of additional equity securities. We cannot predict the effect, if any,
that market sales of those Depositary Shares or the availability of those Depositary Shares for sale will have on the market price of
our Depositary Shares.

| 14 |

You may experience future dilution as a result of future equity offerings.

In order to raise additional
capital, we may in the future offer additional Depositary Shares or other securities convertible into or exchangeable for our Depositary
Shares at prices that may not be the same as the price per share in this offering. We may sell Depositary Shares or other securities in
any other offering at a price per Depositary Share that is less than the price per Depositary Share paid by any investors in this offering,
and investors purchasing shares or other securities in the future could have rights superior to existing Depositary Share holders and
shareholders. The price per Depositary Share at which we sell additional Depositary Shares, or securities convertible or exchangeable
into Depositary Shares, in future transactions may be higher or lower than the price per Depositary Shares paid by any investors in this
offering.

| 15 |

Sales of a substantial number of our Depositary Shares in the public markets, or the perception that such sales could occur, could cause our Depositary Share price to fall.

We may issue and sell additional
Depositary Shares in the public markets, including during this offering. As a result, a substantial number of our Depositary Shares may
be sold in the public market. Sales of a substantial number of our Depositary Shares in the public markets, including during this offering,
or the perception that such sales could occur, could depress the market price of our Depositary Shares and impair our ability to raise
capital through the sale of additional equity securities.

Because we do not currently intend to declare cash dividends on our Depositary Shares in the foreseeable future, Depositary Share holders must rely on appreciation of the